{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:53:14Z","timestamp":1768272794087,"version":"3.49.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver disease worldwide. Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide, with high morbidity and mortality. The rapidly increasing incidence of NAFLD is becoming an essential precursor of HCC globally. MicroRNAs (miRNAs) are involved in the progression of NAFLD and HCC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Potential miRNAs associated with NAFLD in HCC tumorigenesis were identified through a systematic review, and their roles were evaluated by data mining analysis. The biological function of the potential miRNA and its target genes in NAFLD and HCC were evaluated by bioinformatic analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>MIR122 was identified as the potential miRNA associated with NAFLD and HCC. Then, MIR122 expression was significantly lower in HCC patients, and higher MIR122 levels were associated with significantly better overall survival. Next, the biological functions of MIR122 and target genes were predicted to be involved in inflammation, fibrosis, cell proliferation, invasion, metastasis, and apoptosis. In particular, the FOXO signaling pathway may regulate the above biological functions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MIR122 was suggested to be involved in progressing from NAFLD to HCC through the PI3K\/AKT\/FOXO pathway.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p>PROSPERO, identifier: CRD 42024517940.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1462513","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T04:53:03Z","timestamp":1731646383000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the roles of microRNAs associated with nonalcoholic fatty liver disease in hepatocellular carcinoma tumorigenesis: a systematic review and network analysis"],"prefix":"10.3389","volume":"11","author":[{"given":"Qinghua","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoning","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ding","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoke Kqueen","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.3390\/ijms21082986","article-title":"Nutrition and genetics in NAFLD: the perfect binomium","volume":"21","author":"Meroni","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"997018","DOI":"10.3389\/fcimb.2022.997018","article-title":"Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications","volume":"12","author":"Fang","year":"2022","journal-title":"Front Cell Infect Microbiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1101324","DOI":"10.3389\/fimmu.2023.1101324","article-title":"Patient-derived models facilitate precision medicine in liver cancer by remodeling cell-matrix interaction","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2147\/IJN.S349426","article-title":"Advances in nanoliposomes for the diagnosis and treatment of liver cancer","volume":"17","author":"Li","year":"2022","journal-title":"Int J Nanomedicine."},{"key":"B8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/hep.32542","article-title":"NAFLD-related hepatocellular carcinoma: the growing challenge","volume":"77","author":"Shah","year":"2023","journal-title":"Hepatology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jhep.2021.08.012","article-title":"Epidemiology and risk-stratification of NAFLD-associated HCC","volume":"75","author":"Ioannou","year":"2021","journal-title":"J Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12943-022-01529-5","article-title":"Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma","volume":"21","author":"Liu","year":"2022","journal-title":"Mol Cancer"},{"key":"B11","article-title":"MicroRNA regulation of liver cancer stem cells","author":"Lou","year":"2018","journal-title":"Am J Cancer Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5212","DOI":"10.3748\/wjg.v19.i32.5212","article-title":"MicroRNAs and liver cancer associated with iron overload: therapeutic targets unravelled","volume":"19","author":"Greene","year":"2013","journal-title":"World J Gastroenterol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nrgastro.2013.183","article-title":"NAFLD, NASH and liver cancer","volume":"10","author":"Michelotti","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-016-0557-6","article-title":"Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma","volume":"16","author":"Akuta","year":"2016","journal-title":"BMC Gastroenterol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s12072-016-9729-2","article-title":"Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan","volume":"10","author":"Akuta","year":"2016","journal-title":"Hepatol Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/hep4.1445","article-title":"Circulating microRNA-122 and fibrosis stage predict mortality of Japanese patients with histopathologically confirmed NAFLD","volume":"4","author":"Akuta","year":"2020","journal-title":"Hepatol Commun."},{"key":"B17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000519995","article-title":"Dynamics of circulating miR-122 predict liver cancer and mortality in Japanese patients with histopathologically confirmed NAFLD and severe fibrosis stage","volume":"100","author":"Akuta","year":"2022","journal-title":"Oncology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of microRNA biogenesis, mechanisms of actions, and circulation","volume":"9","author":"O'Brien","year":"2018","journal-title":"Front Endocrinol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","article-title":"The role of MicroRNAs in human cancer","volume":"1","author":"Peng","year":"2016","journal-title":"Signal Transduct Target Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.addr.2018.01.009","article-title":"MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis","volume":"129","author":"Su","year":"2018","journal-title":"Adv Drug Deliv Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"14482","DOI":"10.3390\/ijms241914482","article-title":"MicroRNAs and nonalcoholic steatohepatitis: a review","volume":"24","author":"Morishita","year":"2023","journal-title":"Int J Mol Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"21340","DOI":"10.1038\/srep21340","article-title":"Alcoholic hepatitis accelerates early hepatobiliary cancer by increasing stemness and miR-122-mediated HIF-1\u03b1 activation","volume":"6","author":"Ambade","year":"2016","journal-title":"Sci Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/hep.22569","article-title":"Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression","volume":"48","author":"Cheung","year":"2008","journal-title":"Hepatology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"12370","DOI":"10.3390\/ijms232012370","article-title":"The implications of noncoding RNAs in the evolution and progression of nonalcoholic fatty liver disease (NAFLD)-related HCC","volume":"23","author":"Rusu","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3390\/biomedicines9080890","article-title":"Circulating microRNA-21 and microRNA-122 as prognostic biomarkers in hepatocellular carcinoma patients treated with transarterial chemoembolization","volume":"9","author":"Pelizzaro","year":"2021","journal-title":"Biomedicines."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e24541","DOI":"10.1002\/jcla.24541","article-title":"Circulating microRNAs (miR-16, miR-22, miR-122) expression and early diagnosis of hepatocellular carcinoma","volume":"36","author":"Fang","year":"2022","journal-title":"J Clin Lab Anal."},{"key":"B27","doi-asserted-by":"publisher","first-page":"BSR20180525","DOI":"10.1042\/BSR20180525","article-title":"The diagnostic values of circulating miRNAs for hypertension and bioinformatics analysis","volume":"38","author":"Zhang","year":"2018","journal-title":"Biosci Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"815","DOI":"10.7150\/ijbs.20052","article-title":"FOXO signaling pathways as therapeutic targets in cancer","volume":"13","author":"Farhan","year":"2017","journal-title":"Int J Biol Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"7918","DOI":"10.1111\/febs.16221","article-title":"FOXOs: masters of the equilibrium","volume":"289","author":"Gui","year":"2022","journal-title":"FEBS J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"44597","DOI":"10.1038\/srep44597","article-title":"FOXO transcription factors protect against the diet-induced fatty liver disease","volume":"7","author":"Pan","year":"2017","journal-title":"Sci Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tibs.2014.02.003","article-title":"FOXO transcription factors: key regulators of cellular quality control","volume":"39","author":"Webb","year":"2014","journal-title":"Trends Biochem Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.celrep.2016.03.021","article-title":"Integrated regulation of hepatic lipid and glucose metabolism by adipose triacylglycerol lipase and FoxO proteins","volume":"15","author":"Zhang","year":"2016","journal-title":"Cell Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1210\/en.2011-1527","article-title":"Hepatic suppression of foxo1 and Foxo3 causes hypoglycemia and hyperlipidemia in mice","volume":"153","author":"Zhang","year":"2012","journal-title":"Endocrinology."},{"key":"B34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.taap.2017.12.007","article-title":"Leptin suppresses microRNA-122 promoter activity by phosphorylation of foxO1 in hepatic stellate cell contributing to leptin promotion of mouse liver fibrosis","volume":"339","author":"Cao","year":"2018","journal-title":"Toxicol Appl Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"803445","DOI":"10.3389\/fphys.2022.803445","article-title":"MicroRNA-122-5p inhibition improves inflammation and oxidative stress damage in dietary-induced non-alcoholic fatty liver disease through targeting FOXO3","volume":"13","author":"Hu","year":"2022","journal-title":"Front Physiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1213506","DOI":"10.3389\/fphar.2023.1213506","article-title":"Molecular subtypes and scoring tools related to Foxo signaling pathway for assessing hepatocellular carcinoma prognosis and treatment responsiveness","volume":"14","author":"Tu","year":"2023","journal-title":"Front Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"19146","DOI":"10.1074\/jbc.M117.793760","article-title":"NK3 homeobox 1 (NKX3","volume":"292","author":"Jiang","year":"2017","journal-title":"J Biol Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"148021","DOI":"10.1016\/j.gene.2023.148021","article-title":"Molecular mechanism of microRNA-mediated hypoglycemic effect of whole grain highland barley","volume":"895","author":"Qin","year":"2024","journal-title":"Gene."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e0119210","DOI":"10.1371\/journal.pone.0119210","article-title":"Polymorphisms in microRNA target sites of forkhead box O genes are associated with hepatocellular carcinoma","volume":"10","author":"Tan","year":"2015","journal-title":"PLoS ONE."},{"key":"B40","doi-asserted-by":"publisher","first-page":"9239","DOI":"10.3390\/ijms24119239","article-title":"MiR-182-5p is upregulated in hepatic tissues from a diet-induced NAFLD\/NASH\/HCC C57BL\/6J mouse model and modulates Cyld and Foxo1 expression","volume":"24","author":"Compagnoni","year":"2023","journal-title":"Int J Mol Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"100900","DOI":"10.1016\/j.neo.2023.100900","article-title":"Hepatocellular carcinoma-derived FOXO1 inhibits tumor progression by suppressing IL-6 secretion from macrophages","volume":"40","author":"Cui","year":"2023","journal-title":"Neoplasia."},{"key":"B42","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13020-022-00628-1","article-title":"Metabolomics and integrated network pharmacology analysis reveal SNKAF decoction suppresses cell proliferation and induced cell apoptisis in hepatocellular carcinoma via PI3K\/Akt\/P53\/FoxO signaling axis","volume":"17","author":"Guo","year":"2022","journal-title":"Chin Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ccell.2016.02.008","article-title":"Spontaneous hepatocellular carcinoma after the combined deletion of Akt isoforms","volume":"29","author":"Wang","year":"2016","journal-title":"Cancer Cell."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.2174\/0929867321666131228205703","article-title":"FoxO proteins: Regulation and molecular targets in liver cancer","volume":"21","author":"Carbajo-Pescador","year":"2014","journal-title":"Curr Med Chem."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3390\/biomedicines9111639","article-title":"Targeting the PI3K\/Akt\/mTOR pathway in hepatocellular carcinoma","volume":"9","author":"Sun","year":"2021","journal-title":"Biomedicines."},{"key":"B46","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1038\/onc.2015.409","article-title":"Cytoplasmic PML promotes TGF-\u03b2-associated epithelial-mesenchymal transition and invasion in prostate cancer","volume":"35","author":"Buczek","year":"2016","journal-title":"Oncogene."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1016\/j.febslet.2014.07.003","article-title":"FOXO1 3'UTR functions as a ceRNA in repressing the metastases of breast cancer cells via regulating miRNA activity","volume":"588","author":"Yang","year":"2014","journal-title":"FEBS Lett."},{"key":"B48","doi-asserted-by":"publisher","first-page":"613","DOI":"10.4254\/wjh.v6.i8.613","article-title":"Circulating microRNAs in patients with non-alcoholic fatty liver disease","volume":"6","author":"Celikbilek","year":"2014","journal-title":"World J Hepatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.3748\/wjg.v25.i42.6322","article-title":"MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes","volume":"25","author":"Elemeery","year":"2019","journal-title":"World J Gastroenterol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1462513\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T04:53:12Z","timestamp":1731646392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1462513\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":49,"alternative-id":["10.3389\/fmed.2024.1462513"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1462513","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"article-number":"1462513"}}